Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Compugen

Home Clinical Trial Sponsors and OrganizationsCompugen

Compugen

68 employees

Also known as:

cgen

compugen 医疗

cgen.us

compugen ltd

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. It focuses on research and development on immuno-oncology and autoimmune diseases. The company was founded by Eli Mintz, Simchon Faigler, and Amir Natan on February 10, 1993 and is headquartered in Holon, Israel.

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

5

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 1

5

100.0%

Trial Status Distribution

Completed

3

60.0%

Recruiting

2

40.0%

Clinical Trials

Trials sponsored by this organization (5)

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Jul 202560 participants

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Jan 2025200 participants

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Aug 202048 participants

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Mar 202094 participants

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Sep 2018121 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials5
Approvals
News

Back to Organizations